Dr Daniel Coleman, University of Birmingham and Leukaemia UK John Goldman Fellow 2021

Dr Daniel Coleman will be looking at how drugs can be used to target the mutated genes in the cancerous cells in Acute Myeloid Leukaemia (AML) patients. By targeting these mutated RAS genes early on Dr Coleman’s team hope to block the pathway for leukaemia to develop before the cells become malignant. 

Leukaemia remains one of the deadliest cancers, with an overall UK survival rate of just over 50 per cent (2013-2017). Acute myeloid leukaemia (AML) is a cancer of the blood and bone marrow. It is the most common type of acute leukaemia in adults. Current treatments are harsh on the body and usually involve an intensive course of chemotherapy followed by a stem cell transplant.

The relapse rates following stem cell transplants are high and AML is one of the most deadly forms of blood cancer. Further research is vital to improve survival rates as well as the quality of life for those who receive this devastating diagnosis. 

“Acute myeloid leukaemia (AML) is a particularly aggressive blood cancer and most often affects elderly patients. It is therefore often difficult to treat with aggressive chemotherapy as patients are often already quite frail. For this reason, it is important to develop treatments which target just the cancer cells and leave the healthy cells intact.” 

Find out more about our other ground-breaking research and care projects

Read about our prestigious John Goldman Fellowships

With blood cancer being the third biggest cancer killer in the UK, we strive to find better treatments and care to make a difference to those affected by leukaemia and other blood cancers.

We are able to fund vital research such as Dr Coleman's project thanks to the generosity of our supporters. You can help fund our life-saving work by donating today.

Please select a donation amount (required)
Set up a regular payment Donate